Abstract
INTRODUCTION
Due to the Covid-19 pandemic several new serology assays measuring
antibodies to Covid-19 has been released. Because the new assays
have been developed more rapidly than usual and with no consensus on
which epitopes on 2019-nCoV, on which the antibodies should be
measured against (e.g. nucleocapsid, spike protein, receptor binding
Domain). Furthermore, there exists no golden standard on which to
apply or compare to in the development of new tests.
The aim of this project is to verify a number of well documented tests
starting with Roche Elecsys Anti-SARS-CoV-2 assay, measuring
antibodies at recombinant nucleopaside SARS-CoV-2 antibody through
Electro-chemiluminescence immunoassay. All blood samples from the North Zealand area which approximately covers 375,000 citizens, both from General practitioners, specialists and hospital are handled by the Department of clinical Chemistry at North Zealand Hospital, Denmark. The sample collection for the Covid-19 serology cohort covers patients with Covid-19 who have had routine
blood samples drawn in Li-Heparin susplus plasma. The project received
approval from the Danish Data Registry on 20th of March 2020, for
collection of remaining blood following routine measurement on Covid-
19 positive patients.
CONCLUSION: The new ECLIA antibody assay from Roche has the highest sensitivity at >14 days from confirmed positive Covid-19 PCR test. Patient data and results of this statistical analysis indicate that the seroconvention increase with days from a confirmed positive Covid-19 PCR test. To conclude on in-active
antibodies further studies on serodynamics data must be conducted.
Due to the Covid-19 pandemic several new serology assays measuring
antibodies to Covid-19 has been released. Because the new assays
have been developed more rapidly than usual and with no consensus on
which epitopes on 2019-nCoV, on which the antibodies should be
measured against (e.g. nucleocapsid, spike protein, receptor binding
Domain). Furthermore, there exists no golden standard on which to
apply or compare to in the development of new tests.
The aim of this project is to verify a number of well documented tests
starting with Roche Elecsys Anti-SARS-CoV-2 assay, measuring
antibodies at recombinant nucleopaside SARS-CoV-2 antibody through
Electro-chemiluminescence immunoassay. All blood samples from the North Zealand area which approximately covers 375,000 citizens, both from General practitioners, specialists and hospital are handled by the Department of clinical Chemistry at North Zealand Hospital, Denmark. The sample collection for the Covid-19 serology cohort covers patients with Covid-19 who have had routine
blood samples drawn in Li-Heparin susplus plasma. The project received
approval from the Danish Data Registry on 20th of March 2020, for
collection of remaining blood following routine measurement on Covid-
19 positive patients.
CONCLUSION: The new ECLIA antibody assay from Roche has the highest sensitivity at >14 days from confirmed positive Covid-19 PCR test. Patient data and results of this statistical analysis indicate that the seroconvention increase with days from a confirmed positive Covid-19 PCR test. To conclude on in-active
antibodies further studies on serodynamics data must be conducted.
Originalsprog | Engelsk |
---|---|
Publikationsdato | 25 sep. 2021 |
Status | Udgivet - 25 sep. 2021 |